OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions	49
Drug dosing during pregnancy—opportunities for physiologically based pharmacokinetic models	35
Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during	35
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine	32
Fast screening of covariates in population models empowered by machine learning	28
Two heads are better than one: current landscape of integrating QSP and machine learning	26
Recent applications of quantitative systems pharmacology and machine learning models across diseases	24
A kinetic proofreading model for bispecific protein degraders	23
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	22
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	21
Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2	21
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance	19
Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling	19
Population pharmacokinetic model selection assisted by machine learning	17
Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1	17
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	16
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies	16
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome	15
Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits	14
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	14
Integration of physiological changes during the postpartum period into a PBPK framework and prediction of amoxicillin disposition before and shortly after delivery	14
Diffusion through skin in the light of a fractional derivative approach: progress and challenges	12
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	11
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	11
An integrative model of Parkinson’s disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression	11

Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women	9
Application of machine learning based methods in exposure–response analysis	8
What should patients do if they miss a dose of medication? A theoretical approach	8
Reduction of quantitative systems pharmacology models using artificial neural networks	8
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	8
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action	7
Well-tempered MCMC simulations for population pharmacokinetic models	7
Mathematical modeling of mammalian circadian clocks affecting drug and disease responses	7
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment	7
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	7
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	6
Optimal control for colistin dosage selection	6
The rhythm of a preterm neonate’s life: ultradian oscillations of heart rate, body temperature and sleep cycles	6
A pharmacokinetic and pharmacodynamic analysis of drug forgiveness	6
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	6
Applications of cosinor rhythmometry in pharmacology	6
Performance of longitudinal item response theory models in shortened or partial assessments	6
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	6
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	5
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	5
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling	5
Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial	5
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	5
A novel approach for personalized response model: deep learning with individual dropout feature ranking	5
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	5
Application of Brunauer–Emmett–Teller (BET) theory and the Guggenheim–Anderson–de Boer (GAB) equation for concentration-dependent, non-saturable cell–cell interaction dose-responses	5
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	5
Towards a comprehensive assessment of QSP models: what would it take?	5
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT	5
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	4
Exact solutions and equi-dosing regimen regions for multi-dose pharmacokinetics models with transit compartments	4
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	4
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients	4
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases	4
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	4
Delay differential equations based models in NONMEM	4
PBPK modeling of CYP3A and P-gp substrates to predict drug–drug interactions in patients undergoing Roux-en-Y gastric bypass surgery	4
Two compartmental fractional derivative model with general fractional derivative	4
Training the next generation of pharmacometric modelers: a multisector perspective	4
Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included.	4